APA (7th ed.) Citation

MJ, M., A, R., PA, P., M, H., DT, F., B, N., . . . RJ, S. (2018). A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology, 7(5), e1423172. https://doi.org/10.1080/2162402X.2017.1423172

Chicago Style (17th ed.) Citation

MJ, Mooradian, et al. "A Phase II Study of Combined Therapy with a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients with Metastatic Melanoma." Oncoimmunology 7, no. 5 (2018): e1423172. https://doi.org/10.1080/2162402X.2017.1423172.

MLA (9th ed.) Citation

MJ, Mooradian, et al. "A Phase II Study of Combined Therapy with a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients with Metastatic Melanoma." Oncoimmunology, vol. 7, no. 5, 2018, p. e1423172, https://doi.org/10.1080/2162402X.2017.1423172.